lonazn
Shell (LON:SHEL), Endava (NYSE:DAVA), and AstraZeneca (LON:AZN) are the first, second, and third most Googled UK stocks in Europe, respectivelyThe oil and gas industry was the most searched industry by far, topping searches in over one-third (37%) of European countriesTechnology was the second most popular sector, representing one-fifth of Europe’s most Googled UK stocksAccording to a recent study, Shell (SHEL) is Europe’s most Googled UK stock, topping search results in 12 countries. There are over an estimated 460,000 monthly global searches for Shell stock. Q4 2022 hedge fund letters, confe...
ValueWalk
Q4 2022 hedge fund letters, conferences and more BP - 7 FebruaryHaving seen how much money Shell made last year, the pressure is now on BP and the amount of tax the company pays on profits made in the UK. Back in August, BP set aside an extra $800m in respect of the increase in windfall taxes for 2023, and has set aside another $800m adjustment in this quarter’s numbers, which pushes the tax take from the North Sea to $2.5bn. In November, the oil company recorded $8.15bn of underlying replacement cost profit, along with a pledge to buy back another $2.5bn of shares. “While the headline number ...
ValueWalk
Wall Street and Asian markets looking positiveFutures markets are indicating gains of up to 0.5% for UK and EuropeHSBC sinks despite higher earningsBonds recover some of their poise following Sunak appointmentPremier Inn hit be rising costsAstraZeneca drug trial ends with a missWall Street enjoyed a positive session overnight and Asian markets have followed on with broadly positive moves, including China which has steadied after a dramatic session on Monday. Futures markets are indicating gains of up to 0.5% for UK and European stocks this morning, but a lot can change in a trading session. Q3...
ValueWalk
AstraZeneca plc (LON:AZN)’s first half revenue rose 48% to $22.2bn, ignoring the impact of exchange rates. This reflected growth in all divisions apart from Other Medicines. Excluding the impact of the Alexion acquisition, exchange rates, and other one-off costs, operating profit was 71% higher at £1.4bn. This reflected higher-margin treatments making up a greater proportion of sales, which offset a 33% increase in operating costs. Q2 2022 hedge fund letters, conferences and more A brighter outlook for Covid medicines means the group now expects full year revenue to increase by a low twenties ...
ValueWalk
AstraZeneca plc (LON:AZN)’s first quarter revenue beat expectations and rose 60% to $11.4bn ignoring the impact of exchange rates. This was driven by growth in most categories, the contribution of Alexion’s portfolio of products and Covid-vaccine contracts. Cash profits (EBITDA) fell 16% to $2.2bn, lower than market expectations. This reflected costs associated with the Alexion acquisition, including a $1.2bn charge related to the revaluation of Alexion’s inventory. A 36% increase in Research and development costs also contributed to the decline. Q1 2022 hedge fund letters, conferences and mor...
ValueWalk
“Such is the sensitivity on the financial markets right now, temporary confidence can evaporate rapidly and that’s what we’ve seen today after what appears to be another deterioration in relations between Russia and Western powers. The FTSE 100 erased gains in early trading and the DAX in Frankfurt and CAC 40 in Paris fell into negative territory. Q4 2021 hedge fund letters, conferences and more Diplomatic SkirmishesHopes had been raised that a summit could quell tensions but fresh diplomatic skirmishes have broken out, with Kyiv dismissing accusations that Ukranian military units tried to ent...
ValueWalk
Below is a comment from Neil Shah, Director of Research at Edison Group, on the release of AstraZeneca plc (LON:AZN) (NASDAQ:AZN)’s trading results this morning. Q1 2021 hedge fund letters, conferences and more Astrazeneca Delivers A Strong Set Of ResultsNeil Shah, Director of Research Edison Group: “As one of the world’s most discussed companies in recent months, it is no surprise that AstraZeneca has delivered a strong set of results for Q1 this year. The company delivered significant revenue growth of 15% in the quarter to $7,320m, excluding the contribution from the COVID-19 vaccine. Produ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら